Stockscreener 앱 받기
9.69
0.62%
0.06
시간 외 거래:
9.98
0.29
+2.99%
전일 마감가:
$9.63
열려 있는:
$10.06
하루 거래량:
1.03M
Relative Volume:
0.97
시가총액:
$747.00M
수익:
-
순이익/손실:
$-209.96M
주가수익비율:
-3.0665
EPS:
-3.16
순현금흐름:
$-176.27M
1주 성능:
+14.95%
1개월 성능:
-3.20%
6개월 성능:
-26.42%
1년 성능:
+91.12%
1일 변동 폭
$9.575
$10.38
1주일 범위
$8.30
$10.38
52주 변동 폭
$4.93
$17.00
레플리뮨 Stock (REPL) Company Profile
명칭
Replimune Group Inc
전화
(781) 222-9600
주소
500 UNICORN PARK, WOBURN, MA
REPL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
9.69 | 649.84M | 0 | -209.96M | -176.27M | -3.16 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
레플리뮨 Stock (REPL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-28 | 개시 | ROTH MKM | Buy |
| 2023-04-17 | 재개 | Piper Sandler | Overweight |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2020-11-17 | 개시 | BTIG Research | Buy |
| 2020-11-02 | 개시 | Jefferies | Buy |
| 2020-10-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-09-04 | 개시 | ROTH Capital | Buy |
| 2019-07-23 | 개시 | Chardan Capital Markets | Buy |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-04-25 | 개시 | Wedbush | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-08-14 | 개시 | JP Morgan | Overweight |
| 2018-08-14 | 개시 | Leerink Partners | Outperform |
모두보기
레플리뮨 주식(REPL)의 최신 뉴스
Replimune Group (NASDAQ:REPL) Price Target Raised to $22.00 at Piper Sandler - Defense World
Piper Sandler raises Replimune stock price target after updates By Investing.com - Investing.com South Africa
Piper Sandler raises Replimune stock price target after updates - Investing.com Australia
Does Replimune Group Inc (NASDAQ: REPL) Still Need To Convince Analysts? - Stocksregister
Replimune Group (REPL) Price Target Raised by Piper Sandler Analyst | REPL Stock News - GuruFocus
Replimune (REPL) Price Target Raised by Piper Sandler Amid Positive Developments | REPL Stock News - GuruFocus
BNP Paribas Financial Markets Trims Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune (REPL) Highlights Promising RP1 Data at ASCO 2025 | REPL Stock News - GuruFocus
Replimune Presents New Analyses from the IGNYTE Study of RP1 plu - GuruFocus
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting | REPL Stock News - GuruFocus
Replimune Reports Promising Clinical Data for RP1 Plus Nivolumab at ASCO 2025, Highlighting Robust Responses and Safety Profile - Nasdaq
Replimune Presents New Analyses From The IGNYTE Study Of RP1 Plus Nivolumab In Anti-PD1 Failed Melanoma At The 2025 American Society Of Clinical Oncology (ASCO) Annual Meeting - marketscreener.com
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed ... - Enidnews.com
Replimune's RP1 Achieves 33% Response Rate in Anti-PD1 Failed Melanoma Trial | REPL Stock News - Stock Titan
ProShare Advisors LLC Grows Stock Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group (NASDAQ:REPL) Trading Down 5.9% – Time to Sell? - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of “Buy” from Analysts - Defense World
Replimune to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Nuveen Asset Management LLC - Defense World
Why Okta Stock Plunged on Wednesday - The Globe and Mail
HC Wainwright Estimates Replimune Group Q3 Earnings - Defense World
Leerink Partnrs Estimates Replimune Group Q1 Earnings - Defense World
Replimune’s SWOT analysis: biotech firm’s stock poised for growth amid FDA review - Investing.com India
Barclays Remains a Buy on Replimune Group (REPL) - The Globe and Mail
Replimune director sells $260,168 in common stock By Investing.com - Investing.com South Africa
Replimune Group, Inc. (NASDAQ:REPL) Q4 2025 Earnings Call Transcript - Insider Monkey
Replimune (REPL) Plans Major Stock Sale with 25.1M Shares Offeri - GuruFocus
Replimune Group Inc Files For Mixed Shelf Of Up To $250 MillionSEC Filing - marketscreener.com
Replimune (REPL) Announces $250 Million Securities Shelf Filing | REPL Stock News - GuruFocus
Replimune Group, Inc. (REPL) Stock Analysis: An Insight into a Biotech Gem with 141% Upside Potential - DirectorsTalk Interviews
Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance
Stock Traders Buy High Volume of Call Options on Replimune Group (NASDAQ:REPL) - Defense World
Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Replimune director sells $260,168 in common stock - Investing.com Australia
Replimune Group Advances Oncolytic Immunotherapy Pipeline - TipRanks
Replimune’s chief commercial officer sells $30,179 in stock By Investing.com - Investing.com South Africa
Replimune Group, Inc. SEC 10-K Report - TradingView
REPLIMUNE GROUP Earnings Results: $REPL Reports Quarterly Earnings - Nasdaq
Earnings call transcript: Replimune Q1 2025 sees stock drop post-earnings By Investing.com - Investing.com South Africa
Replimune (REPL) Prepares for Landmark Melanoma Treatment Launch - GuruFocus
Earnings call transcript: Replimune Q1 2025 sees stock drop post-earnings - Investing.com Australia
Replimune Group Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Transcript : Replimune Group, Inc., Q4 2025 Earnings Call, May 22, 2025 - marketscreener.com
Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2025 - marketscreener.com
Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides ... - Bluefield Daily Telegraph
Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update - TradingView
Replimune (REPL) Prepares for Landmark Melanoma Treatment Launch | REPL Stock News - GuruFocus
Northern Trust Corp Acquires 40,134 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group (NASDAQ:REPL) Stock Price Up 10.9% – What’s Next? - Defense World
Replimune Group: Analysts Are More Optimistic Than The Market (NASDAQ:REPL) - Seeking Alpha
Replimune Announces Dates for Fiscal Fourth Quarter and Year End - GuruFocus
레플리뮨 (REPL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
0.54%
자본화:
|
볼륨(24시간):